NCT02253966

Brief Summary

Despite improvements in analgesic treatment following total knee arthroplasty (TKA) for osteoarthrosis, a substantial part of patients still have severe acute pain after surgery. It has been suggested that preoperative degree of intraarticular inflammation is associated to postoperative degree of pain and level of function. Furthermore it is known, that patients with preoperative inflammation have hyperalgesia and severe movement related pain. The aim of this study is to investigate the effect of a preoperative intraarticular injection of Methylprednisoloneacetate in reducing acute postoperative pain after total knee arthroplasty in patients with signs of severe pre-operative inflammation and pain.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
48

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Oct 2014

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 29, 2014

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 1, 2014

Completed
Same day until next milestone

Study Start

First participant enrolled

October 1, 2014

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2016

Completed
Last Updated

June 6, 2016

Status Verified

June 1, 2016

Enrollment Period

1.4 years

First QC Date

September 29, 2014

Last Update Submit

June 3, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • Pain

    Pain intensity on a numeric rang scale (NRS) from 0 to 10 upon ambulation 24 hours following surgery

    24 hours postoperatively

Secondary Outcomes (6)

  • Pain

    48 hours postoperatively

  • Pain

    From day 1 to day 14

  • Pain

    From day 1 to day 14

  • Sensitisation

    On day 0 and day 2

  • Inflammation

    On day 0 and day 2

  • +1 more secondary outcomes

Study Arms (2)

Methylprednisoloneacetate

ACTIVE COMPARATOR

Administration of: 1 ml methylprednisoloneacetate 40 mg/ml 5 ml lidocaine 20 mg/ml 4 ml sodium chloride 9 mg/ml as a single intraarticular injection 7 days prior to surgery.

Drug: MethylprednisoloneacetateDrug: LidocaineOther: sodium chloride

Sodium chloride

PLACEBO COMPARATOR

Administration of: 5 ml lidocaine 20 mg/ml 5 ml sodium chloride 9 mg/ml as a singe intraarticular injection 7 days prior to surgery.

Drug: LidocaineOther: sodium chloride

Interventions

Also known as: Depo-Medrol
Methylprednisoloneacetate
MethylprednisoloneacetateSodium chloride
Also known as: saline
MethylprednisoloneacetateSodium chloride

Eligibility Criteria

Age50 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 50 -80
  • Osteoarthrosis
  • Scheduled for primary unilateral TKA
  • Preoperative pain report with NRS \> 5 upon walking
  • Signs of sensitisation in knee

You may not qualify if:

  • Allergies to methylprednisoloneacetate, lidocaine or standard analgesic treatment
  • Deficient written or spoken danish
  • Impairment from psychological or neurological disease
  • Local og systemic infection
  • Immunodeficiency
  • Insulin treated diabetes mellitus
  • Anticoagulant therapy
  • ASA (American Society of Anaesthesia) class \> 3
  • General anaesthesia
  • Alchohol use \> 21 units / week
  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Gentofte Hospital

Hellerup, 2900, Denmark

Location

MeSH Terms

Conditions

Hyperalgesia

Interventions

Methylprednisolone AcetateLidocaineSodium Chloride

Condition Hierarchy (Ancestors)

Somatosensory DisordersSensation DisordersNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

MethylprednisolonePrednisolonePregnadienetriolsPregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsAcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAminesChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, Research Fellow

Study Record Dates

First Submitted

September 29, 2014

First Posted

October 1, 2014

Study Start

October 1, 2014

Primary Completion

March 1, 2016

Study Completion

March 1, 2016

Last Updated

June 6, 2016

Record last verified: 2016-06

Locations